MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression
Alice Salib(UNSW Sydney), Glenn M. Marshall(Children's Cancer Institute Australia)
Cited by 10
Related Papers
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
|Nature Communications|2021|87
TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells
|Oncogene|2010|70
The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis <i>in vivo</i> and reduces skin cancer cell migration <i>in vitro</i>
|The Journal of Pathology|2011|39
Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma
|Molecular Oncology|2015|17
Heterozygous loss of keratinocyte TRIM16 expression increases melanocytic cell lesions and lymph node metastasis
|Journal of Cancer Research and Clinical Oncology|2019|12